Ulcerative Colitis and Marijuana                    (letter – 1990)


Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium.                                                           (full – 2006)


Ulcerative colitis in AKR mice is attenuated by intraperitoneally administered anandamide.         (full – 2008)


Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors.                                                                       (abst – 2008)


Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. (full – 2009)                              


Ulcerative Colitis Induces Changes on the Expression of the Endocannabinoid System in the Human Colonic Tissue                                                               (full – 2009)


Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis.                                                           (abst – 2009) sychotropic_ingredient_of_the_marijuana_plant_Cannabis_sativa_is_protective_in_a_murine_model_of_c olitis_


Cannabis for Ulcerative Colitis and Crohn’s Disease treatment                      (news – 2009)  treatment.aspx


Medical Marijuana and Colitis                       (news – 2009)


The Cannabinoid 1 Receptor (CNR1) 1359 G/A Polymorphism Modulates Susceptibility to Ulcerative Colitis and the Phenotype in Crohn’s Disease                                                            (full – 2010)


Mice lacking cannabinoid CB1-, CB2-receptors or both receptors show increased susceptibility to trinitrobenzene sulfonic acid (TNBS)-induced colitis.                                                                          (full – 2010)










The effects of Delta-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis.                                                          (full – 2010)


The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment.                                                   (abst – 2010)


Cannabidiol Reduces Intestinal Inflammation through the Control of Neuroimmune Axis (full – 2011)                        


Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related systemic inflammation.       (full – 2011)                              


β-Caryophyllene inhibits dextran sulfate sodium-induced colitis in mice through CB2 receptor activation and PPARγ pathway.                                                   (abst – 2011)


Alternative targets within the endocannabinoid system for future treatment of gastrointestinal diseases.  (abst – 2011)                                  


Cannabinoid receptor-2 (CB2) agonist ameliorates colitis in IL-10(-/-) mice by attenuating the activation of T cells and promoting their apoptosis.                                                                      (abst – 2011)


The JNK inhibitor XG-102 protects against TNBS-induced colitis.  (full – 2012)


Topical and Systemic Cannabidiol Improves Trinitrobenzene Sulfonic Acid Colitis in Mice.         (full – 2012)            


The atypical cannabinoid O-1602 shows antitumorigenic effects in colon cancer cells and reduces tumor growth in a colitis-associated colon cancer model                                                              (full – 2012)


The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity.                                                     (abst – 2012)


N-                           02, an atypical cannabinoid, inhibits tumor growth in colitis-associated colon cancer through multiple mechanisms.                  (abst          – 2012)


4-Oxo-1,4-dihydropyridines as Selective CB2 Cannabinoid Receptor Ligands Part 2: Discovery of New Agonists Endowed with Protective Effect Against Experimental Colitis.      (abst – 2012)               


The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity.                                                     (abst – 2012)










The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis.                                                                       (abst – 2013)


Inhibition of p38/Mk2 signaling pathway improves the anti-inflammatory effect of WIN55 on mouse experimental colitis.                                                                        (abst – 2013)


Prostaglandin ethanolamides attenuate damage in a human explant colitis model (abst – 2013)                                  


Share a link for